A Phase 0, Open-Label, Crossover Microdose Pharmacokinetic Study of PRX-P4-003 In Healthy Volunteers
Latest Information Update: 11 Nov 2021
At a glance
- Drugs PRX-P4-003 (Primary)
- Indications Behavioural disorders; Binge-eating disorder
- Focus Pharmacokinetics; Proof of concept
- Sponsors Praxis Bioresearch
- 09 Nov 2021 According to a Praxis Bioresearch media release, data from this study presented at the 14th Clinical Trials on Alzheimer's Disease (CTAD) meeting.
- 14 Sep 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Oct 2021.
- 23 Jun 2021 According to a Praxis Bioresearch media release, data is currently undergoing scientific peer review for publication and/or presentation at the upcoming scientific meetings.